Open AccessRESULTS OF NEPHRON-SPARING SURGERY OF INTRAPARENCHYMAL RENAL TUMORS
Author(s) -
G. G. Khareba,
V.M. Lisovyi,
Д. В. Щукин
Publication year - 2020
Publication title -
aktualʹnì problemi sučasnoï medicini: vìsnik ukraïnsʹkoï medičnoï stomatologìčnoï akademì
Language(s) - English
Resource type - Journals
eISSN - 2077-1126
pISSN - 2077-1096
DOI - 10.31718/2077-1096.20.2.96
Subject(s) - medicine , renal cell carcinoma , nephron , kidney , nephrectomy , kidney disease , urology , renal carcinoma , surgery , radiology , pathology
Surgical treatment is the main therapy for patients with renal cell carcinoma. The current approach in the treatment of kidney tumours has become widely introduced into nephron-sparing surgery. This approach is usually applied in cases of complex surgeries for large-size tumours with intravenous extension, multifocal, and intraparenchymal renal tumours. The purpose of the study was to investigate the results of nephron-sparing surgery for intraparenchymal renal tumours. Material and methods. The results were obtained in the process of nephron-sparing surgery treatment of 701 patients with renal tumours. After the distribution of all patients according to the criterion of "intraparenchymal renal tumours", we assessed 27 (3,9%) cases of nephron-sparing surgery. There were also 674 (96,1%) patients with exophytic renal tumors. Results. We managed to obtain the information about long-term treatment outcomes from 606 (86.4%) patients. There were 25 (4,1%) patients with intraparenchymal renal tumors. The observation of patients showed that there were cases of death and disease progression for various reasons during 46.5±2.1 months on average. The results of the comparative statistical analysis showed that the 5-year overall survival among patients with intraparenchymal renal tumors made up 88.0% of the cases and among the patients with exophytic renal tumors it was 94.8%. The differences were not significant (p> 0.430). At the same time, the 5-year overall progression-free survival was obtained in 88.9% of the patients with intraparenchymal renal tumors and in 95.2% (p <0.041) of patients with exophytic renal tumors. Conclusion. The problem of nephron-sparing treatment of intraparenchymal renal tumors is an urgent issue. Research has shown that such tumors are complex for nephron-sparing surgery, require complex treatment technologies that affect surgical results. At the same time, positive oncological results demonstrate that nephron-sparing treatment is an effective method of treating fully intraparenchymal renal tumors.